Needham biotech analysts hold an analyst/industry conference call
Biotech Analyst Fadia, along with Dr. Justin Long, discuss the factors influencing adoption of Alzheimer’s disease treatments, including ...
Zacks.com on MSN13h
Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?
Key TakeawaysLLY has declined 10.6% this month after disappointing third-quarter results.The drug maker has seen strong ...
BioSpace1d
Leqembi, Kisunla and Beyond: The Next Wave of Alzheimer’s at CTAD 2024
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...
alzheimersnewstoday3d
Modified Kisunla dosing shown to lower risk of ARIA-E in Alzheimer’s
Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.
Eisai lowers Leqembi revenue forecast after rocky entry to market
Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.
GEN6d
Alzheimer’s Drug Shows Slower Cognitive Decline in Lower Tau Patients
After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.